Photo of Thomas R. Spitzer,  MD

Thomas R. Spitzer, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-1124
Fax: (617) 724-1126


TSpitzer@partners.org

Thomas R. Spitzer, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Professor, Medicine, Harvard Medical School
  • Director, Bone Marrow Transplantation, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

The primary focus of my research has been the development of novel strategies for performing HLA-mismatched donor bone marrow transplants and for separating the graft versus malignancy effects of transplantation from clinically significant graft versus host disease. A second aim has been to use bone marrow transplantation as a means of inducing tolerance for solid organ transplantation. We have recently developed a non-myeloablative transplant regimen in which mixed lymphohematopoietic chimerism is reliably induced. This mixed chimerism serves as a platform for subsequent adoptive cellular immunotherapy. Striking anti-tumor responses have been seen in the majority of patients with chemorefractory hematologic malignancies. This mixed chimerism has also been shown to induce donor specific allotolerance in one patient with multiple myeloma and end stage renal disease. Studies are underway to evaluate immunological reconstitution following these transplants, the specific contributions of donor and host cell populations to the multiple hematopoietic lineages, and to further define the potentially separable mechanisms of the graft versus host and graft versus malignancy responses.

Publications

Powered by Harvard Catalyst
  • El-Jawahri A, Li S, Antin JH, Spitzer TR, Armand PA, Koreth J, Nikiforow S, Ballen KK, Ho VT, Alyea EP, Dey BR, McAfee SL, Glotzbecker BE, Soiffer RJ, Cutler CS, Chen YB. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biol Blood Marrow Transplant 2016; 22:910-8. PubMed
  • El-Jawahri AR, Vandusen HB, Traeger LN, Fishbein JN, Keenan T, Gallagher ER, Greer JA, Pirl WF, Jackson VA, Spitzer TR, Chen YA, Temel JS. Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation. Cancer 2015. PubMed
  • Chen YB, Li S, Fisher DC, Driscoll J, Del Rio C, Abramson J, Armand P, Barnes J, Brown J, Cutler C, El-Jawahri A, Ho VT, Hochberg E, McAfee S, Takvorian R, Spitzer TR, Antin JH, Soiffer R, Jacobsen E. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biol Blood Marrow Transplant 2015. PubMed
  • El-Jawahri A, Li S, Ballen KK, Cutler C, Dey BR, Driscoll J, Hunnewell C, Ho VT, McAfee SL, Poliquin C, Saylor M, Soiffer RJ, Spitzer TR, Alyea E, Chen YB. Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. Biol Blood Marrow Transplant 2015. PubMed
  • El-Jawahri AR, Traeger LN, Kuzmuk K, Eusebio JR, Vandusen HB, Shin JA, Keenan T, Gallagher ER, Greer JA, Pirl WF, Jackson VA, Ballen KK, Spitzer TR, Graubert TA, McAfee SL, Dey BR, Chen YB, Temel JS. Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. Cancer 2015; 121:951-9. PubMed
  • Chen YB, Batchelor T, Li S, Hochberg E, Brezina M, Jones S, Del Rio C, Curtis M, Ballen KK, Barnes J, Chi AS, Dietrich J, Driscoll J, Gertsner ER, Hochberg F, LaCasce AS, McAfee SL, Spitzer TR, Nayak L, Armand P. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 2015. PubMed
  • Singh H, Nikiforow S, Li S, Ballen KK, Spitzer TR, Soiffer R, Antin JH, Cutler C, Chen YB. Outcomes and management strategies for graft failure after umbilical cord blood transplantation. Am J Hematol 2014. PubMed
  • Chen YB, Li S, Lane AA, Connolly C, Del Rio C, Valles B, Curtis M, Ballen K, Cutler C, Dey BR, El-Jawahri A, Fathi AT, Ho VT, Joyce A, McAfee S, Rudek M, Rajkhowa T, Verselis S, Antin JH, Spitzer TR, Levis M, Soiffer R. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant 2014. PubMed
  • Waller EK, Logan BR, Harris WA, Devine SM, Porter DL, Mineishi S, McCarty JM, Gonzalez CE, Spitzer TR, Krijanovski OI, Linenberger ML, Woolfrey A, Howard A, Wu J, Confer DL, Anasetti C. Improved survival after transplantation of more donor plasmacytoid dendritic or na├»ve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. J Clin Oncol 2014; 32:2365-72. PubMed
  • Omer AK, Kim HT, Yalamarti B, McAfee SL, Dey BR, Ballen KK, Attar E, Chen YB, Spitzer TR. Engraftment syndrome after allogeneic hematopoietic cell transplantation in adults. Am J Hematol 2014. PubMed
  • Yeh AC, Brunner AM, Spitzer TR, Chen YB, Coughlin E, McAfee S, Ballen K, Attar E, Caron M, Preffer FI, Yeap BY, Dey BR. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20:730-4. PubMed
  • Brunner AM, Kim HT, Coughlin E, Alyea EP, Armand P, Ballen KK, Cutler C, Dey BR, Glotzbecker B, Koreth J, McAfee SL, Spitzer TR, Soiffer RJ, Antin JH, Ho VT, Chen YB. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2013; 19:1374-80. PubMed
  • El-Rayess HM, Refaat MM, Post MD, Spitzer TR, Dey B. Chronic graft-versus-host disease with skin signs suspicious for squamous cell carcinoma. Acta Oncol 2013. PubMed
  • Omer AK, Ziakas PD, Anagnostou T, Coughlin E, Kourkoumpetis T, McAfee SL, Dey BR, Attar E, Chen YB, Spitzer TR, Mylonakis E, Ballen KK. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. Biol Blood Marrow Transplant 2013; 19:1190-6. PubMed
  • Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant 2013. PubMed
  • Ballen K, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, Dey BR, Attar E, McAfee S, Delaney C, McCarthy P, Ball ED, Kamble R, Avigan D, Maziarz RT, Ho VT, Koreth J, Alyea E, Soiffer R, Wingard JR, Boussiotis V, Spitzer TR, Antin JH. Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant 2012; 18:1851-8. PubMed
  • Matar AJ, Crepeau RL, Pathiraja V, Robson S, Fishman JA, Spitzer TR, Sachs DH, Huang CA, Duran-Struuck R. Effects of mobilization regimens in donors on outcomes of hematopoietic cell transplantation in miniature Swine. Comp Med 2013; 62:487-94. PubMed
  • Spitzer TR. Microtransplantation: a new paradigm for the separation of graft versus host disease and graft versus tumor? J Clin Oncol 2012; 30:4051-2. PubMed
  • Duran-Struuck R, Matar A, Crepeau R, Gusha A, Schenk M, Hanekamp I, Pathiraja V, Spitzer TR, Sachs DH, Huang CA. Lack of antidonor alloantibody does not indicate lack of immune sensitization: studies of graft loss in a haploidentical hematopoietic cell transplantation swine model. Biol Blood Marrow Transplant 2012; 18:1629-37. PubMed
  • Spitzer TR, Dey BR, Chen YB, Attar E, Ballen KK. The expanding frontier of hematopoietic cell transplantation. 2012; 82:271-9. PubMed
  • Crepeau R, Matar A, Spitzer TR, Robson S, Pathiraja V, Sachs DH, Huang CA, Duran-Struuck R. Edema and tetraparesis in a miniature pig after allogeneic hematopoietic cell transplantation. Comp Med 2012; 62:298-302. PubMed
  • Chen YB, McDonough S, Hasserjian R, Chen H, Coughlin E, Illiano C, Park IS, Jagasia M, Spitzer TR, Cutler CS, Soiffer RJ, Ritz J. Expression of CD30 in patients with acute graft-versus-host disease. Blood 2012; 120:691-6. PubMed
  • Spitzer TR, Sykes M, Tolkoff-Rubin N, Kawai T, McAfee SL, Dey BR, Ballen K, Delmonico F, Saidman S, Sachs DH, Cosimi AB. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011; 91:672-6. PubMed
  • LoCascio SA, Morokata T, Chittenden M, Preffer FI, Dombkowski DM, Andreola G, Crisalli K, Kawai T, Saidman SL, Spitzer TR, Tolkoff-Rubin N, Cosimi AB, Sachs DH, Sykes M. Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation 2010; 90:1607-15. PubMed
  • Heher EC, Spitzer TR. Hematopoietic stem cell transplantation in patients with chronic kidney disease. Semin Nephrol 2010; 30:602-14. PubMed
  • Heher EC, Goes NB, Spitzer TR, Raje NS, Humphreys BD, Anderson KC, Richardson PG. Kidney disease associated with plasma cell dyscrasias. Blood 2010; 116:1397-404. PubMed
  • Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M, Reynolds C, Liney D, Kao G, Ho V, Armand P, Koreth J, Alyea E, Dey BR, Attar E, Spitzer T, Boussiotis VA, Ritz J, Soiffer R, Antin JH, Ballen K. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant 2010. PubMed
  • Krause DS, Spitzer TR, Stowell CP. The concentration of CD44 is increased in hematopoietic stem cell grafts of patients with acute myeloid leukemia, plasma cell myeloma, and non-Hodgkin lymphoma. Arch Pathol Lab Med 2010; 134:1033-8. PubMed
  • Ballen KK, Cutler C, Yeap BY, McAfee SL, Dey BR, Attar EC, Chen YB, Haspel RL, Liney D, Koreth J, Ho V, Alyea EP, Soiffer RJ, Spitzer TR, Antin JH. Donor Derived Second Hematologic Malignancies after Cord Blood Transplantation. Biol Blood Marrow Transplant 2010; 16:1025-31. PubMed
  • Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB, Chen AR, Krishnan A, Kernan NA, Avigan DE, Spitzer TR, Shulman HM, Di Salvo DN, Revta C, Warren D, Momtaz P, Bradwin G, Wei LJ, Iacobelli M, McDonald GB, Guinan EC. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multi-organ failure post stem cell transplantation: a multi-center, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010; 16:1005-17. PubMed
  • Duran-Struuck R, Cho PS, Teague AG, Fishman B, Fishman AS, Hanekamp JS, Moran SG, Wikiel KJ, Ferguson KK, Lo DP, Duggan M, Arn JS, Billiter B, Horner B, Houser S, Yeap BY, Westmoreland SV, Spitzer TR, McMorrow IM, Sachs DH, Bronson RT, Huang CA. Myelogenous leukemia in adult inbred MHC-defined miniature swine: A model for human myeloid leukemias. 2010; 135:243-56. PubMed
  • Brown JA, Stevenson K, Kim HT, Cutler C, Ballen K, McDonough S, Reynolds C, Herrera M, Liney D, Ho V, Kao G, Armand P, Koreth J, Alyea E, McAfee S, Attar E, Dey B, Spitzer T, Soiffer R, Ritz J, Antin JH, Boussiotis VA. Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood 2010; 115:4111-9. PubMed
  • Chen YB, Hochberg EP, Feng Y, Neuberg D, Rawal B, Motyckova G, Fisher DC, McAfee SL, Spitzer TR, Lacasce AS. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients Leuk Lymphoma 2010; 51:789-96. PubMed
  • Ulrickson M, Aldridge J, Kim HT, Hochberg EP, Hammerman P, Dube C, Attar E, Ballen KK, Dey BR, McAfee SL, Spitzer TR, Chen YB. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant 2009; 15:1447-54. PubMed
  • Dey BR, Spitzer TR, Hasserjian RP. Case records of the Massachusetts General Hospital. Case 28-2009. A 68-year-old man with fatigue, cough, and peripheral-blood monocytosis. N Engl J Med 2009; 361:1099-106. PubMed
  • Chen YB, Kim HT, McDonough S, Odze RD, Yao X, Lazo-Kallanian S, Spitzer TR, Soiffer R, Antin JH, Ritz J. Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15:1066-76. PubMed
  • Delaney M,Cutler CS,Haspel RL,Yeap BY,McAfee SL,Dey BR,Attar E,Kao G,Alyea EP,Koreth J,Ho VT,Saidman S,Liney D,Sese D,Soiffer RJ,Spitzer TR,Antin JH,Ballen KK. High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion 2009; 49:995-1002. PubMed
  • Heher EC,Spitzer TR,Goes NB. Light chains: heavy burden in kidney transplantation. Transplantation 2009; 87:947-52. PubMed
  • Yusuf RZ, Dey B, Yeap BY, McAfee S, Attar E, Sepe PS, Dube C, Spitzer TR, Ballen KK. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2009; 43:37-42. PubMed
  • Ting DT, Spitzer TR, Chaudhary A, Muzikansky A, Colby C, Power K, McAfee S, Ballen K, Attar E, Saidman SL, Preffer F, Sykes M, Dey BR. Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT. Bone Marrow Transplant 2008; 42:329-35. PubMed
  • Haspel RL, Kao G, Yeap BY, Cutler C, Soiffer RJ, Alyea EP, Ho VT, Koreth J, Dey BR, McAfee SL, Attar EC, Spitzer T, Antin JH, Ballen KK. Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant 2008; 41:523-9. PubMed
  • Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, Shaffer J, Preffer FI, Ding R, Sharma V, Fishman JA, Dey B, Ko DS, Hertl M, Goes NB, Wong W, Williams WW, Colvin RB, Sykes M, Sachs DH. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-61. PubMed
  • Chen YB, Spitzer TR. Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors. Leukemia 2007; 22:31-41. PubMed
  • Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2007; 14:59-66. PubMed
  • Park JH, Spitzer T, Kuter DJ. Successful treatment of pure red cell aplasia with autologous stem cell transplantation. Am J Hematol 2007; 82:812-4. PubMed
  • Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, Konopleva M, Antin JH, Spitzer TR. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant 2007; 13:838-43. PubMed
  • Dey BR, Shaffer J, Yee AJ, McAfee S, Caron M, Power K, Ting DT, Colby C, Preffer F, Ballen K, Attar E, Saidman S, Tarbell N, Sachs D, Sykes M, Spitzer TR. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant 2007; 40:19-27. PubMed
  • Shaffer J, Villard J, Means TK, Alexander S, Dombkowski D, Dey BR, McAfee S, Ballen KK, Saidman S, Preffer FI, Sachs DH, Spitzer TR, Sykes M. Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol 2007; 35:1140-52. PubMed
  • Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, Haspel R, Kao G, Liney D, Alyea E, Lee S, Cutler C, Ho V, Soiffer R, Antin JH. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13:82-9. PubMed
  • Fudaba Y, Spitzer TR, Shaffer J, Kawai T, Fehr T, Delmonico F, Preffer F, Tolkoff-Rubin N, Dey BR, Saidman SL, Kraus A, Bonnefoix T, McAfee S, Power K, Kattleman K, Colvin RB, Sachs DH, Cosimi AB, Sykes M. Myeloma Responses and Tolerance Following Combined Kidney and Nonmyeloablative Marrow Transplantation: In Vivo and In Vitro Analyses. Am J Transplant 2006; 6:2121-33. PubMed
  • Cina RA, Wikiel KJ, Lee PW, Cameron AM, Hettiarachy S, Rowland H, Goodrich J, Colby C, Spitzer TR, Neville DM, Huang CA. Stable multilineage chimerism without graft versus host disease following nonmyeloablative haploidentical hematopoietic cell transplantation. Transplantation 2006; 81:1677-85. PubMed
  • Lazarus HM, P. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 2006; 132:755-69. PubMed
  • Dey BR, McAfee S, Colby C, Cieply K, Caron M, Saidman S, Preffer F, Shaffer J, Tarbell N, Sackstein R, Sachs D, Sykes M, Spitzer TR. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005; 128:351-9. PubMed
Hide